179 related articles for article (PubMed ID: 15965274)
1. Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Kosmas C; Tsavaris NB; Soukouli G; Gouveris P; Tsakonas G; Katselis J; Alexopoulos H; Mylonakis N; Karabelis A
Med Oncol; 2005; 22(2):123-8. PubMed ID: 15965274
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid tumor marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Kosmas C; Tsavaris NB; Tsakonas G; Soukouli G; Gassiamis A; Mylonakis N; Karabelis A
Med Sci Monit; 2005 Aug; 11(8):CR398-401. PubMed ID: 16049383
[TBL] [Abstract][Full Text] [Related]
3. HMFG1 antigen: a new marker for carcinomatous meningitis.
Moseley RP; Oge K; Shafqat S; Moseley CM; Sullivan NM; Badley RA; Burchell J; Taylor-Papadimitriou J; Coakham HB
Int J Cancer; 1989 Sep; 44(3):440-4. PubMed ID: 2777410
[TBL] [Abstract][Full Text] [Related]
4. [Carcinomatous meningitis presenting with isolated headache].
Outteryck O; Berteloot D; Senechal O; Fromentin C; Mounier-Vehier F
Rev Neurol (Paris); 2004 Oct; 160(10):949-51. PubMed ID: 15492724
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
Groves MD; Hess KR; Puduvalli VK; Colman H; Conrad CA; Gilbert MR; Weinberg J; Cristofanilli M; Yung WK; Liu TJ
J Neurooncol; 2009 Sep; 94(2):229-34. PubMed ID: 19267183
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.
Stockhammer G; Poewe W; Burgstaller S; Deisenhammer F; Muigg A; Kiechl S; Schmutzhard E; Maier H; Felber S; Schumacher P; Gunsilius E; Gastl G
Neurology; 2000 Apr; 54(8):1670-6. PubMed ID: 10762512
[TBL] [Abstract][Full Text] [Related]
7. Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Kosmas C; Malamos NA; Tsavaris NB; Stamataki M; Gregoriou A; Rokana S; Vartholomeou M; Antonopoulos MJ
Oncology; 2002; 63(1):6-15. PubMed ID: 12187065
[TBL] [Abstract][Full Text] [Related]
8. Tissue polypeptide antigen activity in cerebrospinal fluid: a marker of central nervous system metastases of breast cancer.
Bach F; Soletormos G; Dombernowsky P
J Natl Cancer Inst; 1991 Jun; 83(11):779-84. PubMed ID: 2041052
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and treatment of carcinoid meningitis: a challenge to the neurologist and oncologist].
Rudnicka H; Niwińska A; Gruszfeld A; Pieńkowski T
Neurol Neurochir Pol; 2003; 37(4):811-24. PubMed ID: 14746241
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.
Glantz MJ; Hall WA; Cole BF; Chozick BS; Shannon CM; Wahlberg L; Akerley W; Marin L; Choy H
Cancer; 1995 Jun; 75(12):2919-31. PubMed ID: 7773943
[TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical demonstration of carcinoembryonic antigen in cerebrospinal fluid with carcinomatous meningitis from rectal cancer.
Kobayashi TK; Yamaki T; Yoshino E; Higuchi T; Kamachi M
Acta Cytol; 1984; 28(4):430-4. PubMed ID: 6380184
[TBL] [Abstract][Full Text] [Related]
12. A simple method for discrimination of carcinomatous meningitis using CEA, total protein, and total cell count in the cerebrospinal fluid of primary lung cancer patients.
Ogawa Y; Saraya T; Noda A; Kurokawa N; Sakuma S; Aso K; Mikura S; Oda M; Ishida M; Honda K; Nakamoto K; Tamura M; Takata S; Ishii H; Takizawa H
Medicine (Baltimore); 2021 Apr; 100(14):e25367. PubMed ID: 33832119
[TBL] [Abstract][Full Text] [Related]
13. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers.
Chamberlain MC
Neurology; 1998 Apr; 50(4):1173-5. PubMed ID: 9566421
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid tumor markers predict treatment response in a patient with carcinomatous meningitis.
Lin J; Wu S; Tian C; Shi Q
J Int Med Res; 2021 Jan; 49(1):300060520987946. PubMed ID: 33512249
[TBL] [Abstract][Full Text] [Related]
15. [Four cases of meningeal metastasis originating from breast cancer].
Kashiwagi S; Asano Y; Watanabe M; Morisaki T; Aomatsu N; Nakamura M; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1917-9. PubMed ID: 23267929
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy.
van Zanten AP; Twijnstra A; Ongerboer de Visser BW; van Heerde P; Hart AA; Nooyen WJ
J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):119-23. PubMed ID: 2019836
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis.
Hovestadt A; Henzen-Logmans SC; Vecht CJ
Br J Cancer; 1990 Oct; 62(4):653-4. PubMed ID: 2223585
[TBL] [Abstract][Full Text] [Related]
18. Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors.
Nakagawa H; Kubo S; Murasawa A; Nakajima S; Nakajima Y; Izumoto S; Hayakawa T
J Neurooncol; 1992 Feb; 12(2):111-20. PubMed ID: 1560255
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers.
Corsini E; Bernardi G; Gaviani P; Silvani A; de Grazia U; Ciusani E; Croci D; Salmaggi A
Clin Chem Lab Med; 2009; 47(7):874-9. PubMed ID: 19453289
[TBL] [Abstract][Full Text] [Related]
20. Carcinomatous meningitis as the presenting manifestation of gallbladder carcinoma: case report and review of the literature.
Shen Y; Blumenthal DT; Digre K; Cessna MH; Gopez EV
J Neurooncol; 2004 Oct; 70(1):67-71. PubMed ID: 15527109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
